Clinical Trial Update: A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study [Phase 3]

View source ↗

Summary

Phase III study comparing DE-117 ophthalmic solution to timolol for glaucoma or ocular hypertension; trial completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• DE-117 Ophthalmic Solution (DE-117)
• Timolol maleate ophthalmic solution 0.5% (timolol maleate ophthalmic solution 0.5%)

Snippet

Sponsor: Santen Inc. | Conditions: Glaucoma and Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2023-08-09